Assessment of the safety of nivolumab in people living with HIV with advanced cancer on antiretroviral therapy: the AIDS Malignancy Consortium 095 Study

By sjmartinez • November 15, 2023

Rajdev L, Jackie Wang CC, Joshi H, Lensing S, Lee J, Ramos JC, Baiocchi R, Ratner L, Rubinstein PG, Ambinder R, Henry D, Streicher H, Little RF, Chiao E, Dittmer DP, Einstein MH, Cesarman E, Mitsuyasu R, Sparano JA; AIDS Malignancy Consortium. Assessment of the safety of nivolumab in people living with HIV with advanced cancer on antiretroviral therapy: the AIDS Malignancy Consortium 095 Study. Cancer. 2023 Nov 14. doi: 10.1002/cncr.35110. Epub ahead of print. PMID: 37962072.

Tags: CD4 count >100/µL, HIV cancer, immunotherapy, Infectious Diseases, nivolumab, Publications

Pitavastatin effects on lipids in relation to major adverse cardiovascular events: a REPRIEVE secondary analysis

Umbleja T, Zafar MU, McCallum S, Gattu AK, Zanni MV, Bloomfield GS, Malvestutto CD, Fichtenbaum CJ, Currier JS, Sponseller CA, Diggs MR, Chu SM, Lu[...]

Non-canonical IL-22 receptor signaling remodels the oral mucosal barrier during Candida albicans immunosurveillance

Millet N, Sekar J, Solis NV, Miao J, Millet A, Aggor FEY, Wildeman A, Cook ME, Davari A, Peters BM, Lionakis MS, Gaffen SL, Jendzjowsky[...]

2025 Clinical Practice Guideline Update by the Infectious Diseases Society of America on the Treatment and Management of COVID-19: Baricitinib vs. Tocilizumab

Nadig N, Bhimraj A, Cawcutt K, Chiotos K, Dzierba AL, Kim AY, Martin GS, Pearson JC, Shumaker AH, Baden LR, Bedimo R, Cheng VC, Chew[...]